Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

3008 - Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)


10 Oct 2016


Non-metastatic NSCLC and other thoracic malignancies


Lecia Sequist


Annals of Oncology (2016) 27 (6): 493-496. 10.1093/annonc/mdw389


L.V. Sequist1, A. Chiang2, J. Gilbert3, M. Gordon4, P.R. Conkling5, D. Thompson6, J..P. Marcoux7, S.J. Antonia8, B. Liu9, D.S. Shames10, A. Lopez-Chavez9, C. O'Hear11, M. Fasso11, S. Gettinger2

Author affiliations

  • 1 Center For Thoracic Cancers, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Yale Cancer Center, Yale School of Medicine, New Haven/US
  • 3 Oncology, Vanderbilt University School of Medicine, Nashville/US
  • 4 Division Of Arizona Center For Cancer Care, Pinnacle Oncology Hematology, Scottsdale/US
  • 5 Virginia Oncology Associates, US Oncology Research, Norfolk/US
  • 6 Oncology, Sarah Cannon Research Institute, Nashville/US
  • 7 Thoracic Oncology, Dana Farber Cancer Institute, Boston/US
  • 8 Department Of Thoracic Oncology, Moffitt Cancer Center, Tampa/US
  • 9 Product Development Oncology, Genentech, Inc., South San Francisco/US
  • 10 Oncology Biomarker Department, Genentech, Inc., South San Francisco/US
  • 11 Product Development Oncology, Genentech Inc, A Member of the Roche Group, 94080 - South San Francisco/US


Abstract 3008


Most patients (pts) with ES-SCLC receive platinum-based chemotherapy with etoposide, however median survival is


ES-SCLC pts received atezo IV q3w at 15 mg/kg or 1200 mg as part of a Ph Ia study (NCT01375842). Due to protocol amendments the first 5 pts were PD-L1 selected and the subsequent 12 were not PD-L1 selected. Initially treatment was to last up to 1 y though retreatment at PD was allowed. Later pts were treated until loss of clinical benefit. RECIST v1.1 and irRC assessments were used. PD-L1 expression was centrally evaluated using the VENTANA SP142 IHC assay. Teffector (Teff) gene signature (CD8A, GZMA, GZMB, EOMES, CXCL9, CXCL10, TBX21) and PD-L1 mRNA was measured (iChip).


As of Dec 15, 2015, 17 pts with a minimum follow-up of 6.7 mo, were safety/efficacy evaluable. 65% were male; 88% were ECOG PS 1. Median age was 63 y (range 44-80), and pts were heavily pretreated (65% ≥ 3 prior therapies). 65% pts had all grade (1-5) treatment-related AEs most often fatigue (24%). There were 8 related G3-5 AEs in 3 pts, including 1 G3 pneumonitis leading to treatment discontinuation and 1 G5 hepatic failure. Confirmed ORR by RECIST was 6% (1 PR with DOR of 7 mo, also irPR by irRC) and 24% by irRC. 4/17 pts received atezo for ≥ 6 mo, 2 of these for ≥ 12 mo. 1 irPR pt stopped atezo per protocol after 1 y and remained in irPR for an additional 1 y until PD. Upon retreatment, the patient again derived benefit and is still on atezo as of data cutoff, 2.6 y from first dose. mPFS by RECIST was 1.5 mo (95% CI: 1.2, 2.7), and mOS was 5.9 mo (95% CI: 4.3, 20.1). PD-L1 expression was low overall, consistent with published data. A trend toward greater clinical benefit was seen for Teff gene signature and PD-L1 mRNA.


These initial results in ES-SCLC demonstrate a tolerable safety profile with no new safety signals for atezo. Atezo also showed encouraging single-agent activity, based on the duration of clinical benefit in a subset of patients. Further studies of atezo in ES-SCLC are planned.

Clinical trial identification


Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.


F. Hoffmann-La Roche Ltd.


L.V. Sequist: Consulting: uncompensated consulting with BI, Clovis, Merrimack, Novartis, Genentech, Taiho, and consulting with AZ, Ariad Research: BI, AZ, Clovis, Merrimack, Merck, Novartis, Genentech. A. Chiang: Genentech/Roche Advisory Board Research funding for trials: Boehringer Ingelheim, OncoMed, Millenium, Onyx. J. Gilbert: Research funding (for clinical trials, not salary) from AZ, Merck, Pfizer, Threshold. M. Gordon: Research funding from Genentech and Roche for research activities which is provided to the institution. P.R. Conkling: Research funding: USOncology Research. S.J. Antonia: Honoraria: BMS, AstraZeneca, Advisory boards: Genetech, Merck Consulting: BMS, AstraZeneca Research: Medimmune Travel: BMS, AstraZeneca. B. Liu, D.S. Shames, A. Lopez-Chavez: Genentech employee. C. O'Hear: Genentech Employee. Stocker/other ownership: Genentech/Roche. Research funding from Genentech. M. Fasso: Genentech Employee and Aduro Bio Tech, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings